301 related articles for article (PubMed ID: 24093956)
1. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
[TBL] [Abstract][Full Text] [Related]
2. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
3. Mannose-mediated inhibitory effects of PA-MSHA on invasion and metastasis of hepatocellular carcinoma via EGFR/Akt/IκBβ/NF-κB pathway.
Li T; Dong ZR; Guo ZY; Wang CH; Zhi XT; Zhou JW; Li DK; Chen ZT; Chen ZQ; Hu SY
Liver Int; 2015 Apr; 35(4):1416-29. PubMed ID: 25066210
[TBL] [Abstract][Full Text] [Related]
4. The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression.
Gahr S; Mayr C; Kiesslich T; Illig R; Neureiter D; Alinger B; Ganslmayer M; Wissniowski T; Fazio PD; Montalbano R; Ficker JH; Ocker M; Quint K
Int J Oncol; 2015 Sep; 47(3):963-70. PubMed ID: 26202945
[TBL] [Abstract][Full Text] [Related]
5. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity.
Woods DM; Woan K; Cheng F; Wang H; Perez-Villarroel P; Lee C; Lienlaf M; Atadja P; Seto E; Weber J; Sotomayor EM; Villagra A
Melanoma Res; 2013 Oct; 23(5):341-8. PubMed ID: 23963286
[TBL] [Abstract][Full Text] [Related]
6. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3.
Subramaniam A; Shanmugam MK; Ong TH; Li F; Perumal E; Chen L; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Hui KM; Sethi G
Br J Pharmacol; 2013 Oct; 170(4):807-21. PubMed ID: 23848338
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.
Qian DZ; Kato Y; Shabbeer S; Wei Y; Verheul HM; Salumbides B; Sanni T; Atadja P; Pili R
Clin Cancer Res; 2006 Jan; 12(2):634-42. PubMed ID: 16428510
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
[TBL] [Abstract][Full Text] [Related]
9. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
10. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
[TBL] [Abstract][Full Text] [Related]
11. Da-Chai-Hu-Tang Formula inhibits the progression and metastasis in HepG2 cells through modulation of the PI3K/AKT/STAT3-induced cell cycle arrest and apoptosis.
Duan ZW; Liu Y; Zhang PP; Hu JY; Mo ZX; Liu WQ; Ma X; Zhou XH; Wang XH; Hu XH; Wei SL
J Ethnopharmacol; 2024 Sep; 331():118293. PubMed ID: 38705430
[TBL] [Abstract][Full Text] [Related]
12. Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells.
Edwards A; Li J; Atadja P; Bhalla K; Haura EB
Mol Cancer Ther; 2007 Sep; 6(9):2515-24. PubMed ID: 17876048
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat).
Kubo M; Kanaya N; Petrossian K; Ye J; Warden C; Liu Z; Nishimura R; Osako T; Okido M; Shimada K; Takahashi M; Chu P; Yuan YC; Chen S
Breast Cancer Res Treat; 2013 Jan; 137(1):93-107. PubMed ID: 23160924
[TBL] [Abstract][Full Text] [Related]
14. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.
Tate CR; Rhodes LV; Segar HC; Driver JL; Pounder FN; Burow ME; Collins-Burow BM
Breast Cancer Res; 2012 May; 14(3):R79. PubMed ID: 22613095
[TBL] [Abstract][Full Text] [Related]
15. Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
Sakurai T; Yada N; Hagiwara S; Arizumi T; Minaga K; Kamata K; Takenaka M; Minami Y; Watanabe T; Nishida N; Kudo M
Cancer Sci; 2017 Oct; 108(10):1996-2003. PubMed ID: 28777492
[TBL] [Abstract][Full Text] [Related]
16. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells.
Lin Z; Zhang Z; Jiang X; Kou X; Bao Y; Liu H; Sun F; Ling S; Qin N; Jiang L; Yang Y
Oncotarget; 2017 Mar; 8(11):17833-17848. PubMed ID: 28147319
[TBL] [Abstract][Full Text] [Related]
17. (-)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma.
Pei T; Meng Q; Han J; Sun H; Li L; Song R; Sun B; Pan S; Liang D; Liu L
Oncotarget; 2016 Jul; 7(28):43475-43491. PubMed ID: 27259268
[TBL] [Abstract][Full Text] [Related]
18. KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling.
Han J; Wang F; Lan Y; Wang J; Nie C; Liang Y; Song R; Zheng T; Pan S; Pei T; Xie C; Yang G; Liu X; Zhu M; Wang Y; Liu Y; Meng F; Cui Y; Zhang B; Liu Y; Meng X; Zhang J; Liu L
Oncogene; 2019 Jan; 38(3):406-420. PubMed ID: 30115976
[TBL] [Abstract][Full Text] [Related]
19. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
20. The pan-deacetylase inhibitor panobinostat inhibits growth of hepatocellular carcinoma models by alternative pathways of apoptosis.
Di Fazio P; Schneider-Stock R; Neureiter D; Okamoto K; Wissniowski T; Gahr S; Quint K; Meissnitzer M; Alinger B; Montalbano R; Sass G; Hohenstein B; Hahn EG; Ocker M
Cell Oncol; 2010 Jan; 32(4):285-300. PubMed ID: 20208142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]